Peringatan Keamanan

There is limited information regarding the LD₅₀ and overdose of vWF.

Von Willebrand factor human

DB13133

biotech approved investigational

Deskripsi

The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis. It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the site of blood vessel injury and stabilizing procoagulant factor VIII (FVIII).^A32262 Exogenous sources of vWF are used to restore functional levels of vWF in blood disorders associated with deficient or abnormal blood clotting. The human vWF is used to manage and control bleeding episodes in patients with von Willebrand disease and hemophilia A. It was first approved by the FDA in 2015.^L40049 As vWF is normally present in the blood as a stable complex with coagulation factor III, therapeutic vWF products are also available as a combination product with antihemophilic factor human.^L1878 A recombinant form of vWF, vonicog alfa, is also available to enhance production and avoid the theoretical risk of pathogen transmission from plasma donors.^A32262

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) In patients with Type 3 von Willebrand disease who were previously treated on-demand with any vWF product prior to study entry, the mean (SD) half-life of recombinant vWF at steady state was 16.5 (4.13) hours. In patients who were previously treated prophylactically with a plasma-derived vWF product, the mean (SD) half-life was 14.1 (6.13) hours.[L40049]

Volume Distribusi The volume of distribution of the human concentrate vWF is 69.7 mL/kg.[A32270]

Klirens (Clearance) In patients with Type 3 von Willebrand disease who were previously treated on-demand with any vWF product prior to study entry, the mean (SD) clearance of recombinant vWF at steady state was 0.04 (0.012) (dL/kg)/h. In patients who were previously treated prophylactically with a plasma-derived vWF product, the mean (SD) clearance was 0.04 (0.014) (dL/kg)/h.[L40049]

Absorpsi

In patients with Type 3 von Willebrand disease who were previously treated on-demand with any vWF product prior to study entry, the mean (SD) C_max of recombinant vWF at steady state was 86.4 (34.2) IU/dL. In patients who were previously treated prophylactically with a plasma-derived vWF product, the mean (SD) C_max was 90.6 (33.7) IU/dL.^L40049

Metabolisme

ADAMTS13, or von Willebrand factor-cleaving protease, is a disintegrin and metalloprotease that normally cleaves vWF.^A32262 Proteolysis of vWF occurs primarily in the cleavage site at domain A2, which is a target domain for ADAMTS13.^A32290

Rute Eliminasi

As with endogenous vWF, exogenous sources of vWF are also expected to undergo elimination by the liver and spleen, which take up vWF as part of an active regulatory mechanism.^A32266

Interaksi Obat

92 Data

Aminocaproic acid	The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Von Willebrand factor human.
Alpha-1-proteinase inhibitor	Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Von Willebrand factor human.
Menadione	Menadione may increase the thrombogenic activities of Von Willebrand factor human.
Tranexamic acid	Tranexamic acid may increase the thrombogenic activities of Von Willebrand factor human.
Aprotinin	Aprotinin may increase the thrombogenic activities of Von Willebrand factor human.
Hydrogen peroxide	Hydrogen peroxide may increase the thrombogenic activities of Von Willebrand factor human.
Aminomethylbenzoic acid	Aminomethylbenzoic acid may increase the thrombogenic activities of Von Willebrand factor human.
Camostat	Camostat may increase the thrombogenic activities of Von Willebrand factor human.
Menadione bisulfite	Menadione bisulfite may increase the thrombogenic activities of Von Willebrand factor human.
Monteplase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Monteplase.
Lepirudin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Lepirudin.
Bivalirudin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Bivalirudin.
Alteplase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Alteplase.
Urokinase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Urokinase.
Reteplase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Reteplase.
Anistreplase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Anistreplase.
Tenecteplase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Tenecteplase.
Abciximab	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Abciximab.
Drotrecogin alfa	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Drotrecogin alfa.
Streptokinase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Streptokinase.
Dicoumarol	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dicoumarol.
Argatroban	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Argatroban.
Ardeparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Ardeparin.
Phenindione	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Phenindione.
Fondaparinux	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Fondaparinux.
Warfarin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Warfarin.
Pentosan polysulfate	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Pentosan polysulfate.
Phenprocoumon	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Phenprocoumon.
Dipyridamole	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dipyridamole.
Heparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Heparin.
Enoxaparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Enoxaparin.
Epoprostenol	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Epoprostenol.
Acenocoumarol	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Acenocoumarol.
4-hydroxycoumarin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with 4-hydroxycoumarin.
Coumarin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Coumarin.
Ximelagatran	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Ximelagatran.
Desmoteplase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Desmoteplase.
Defibrotide	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Defibrotide.
Ancrod	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Ancrod.
Beraprost	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Beraprost.
Prasugrel	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Prasugrel.
Rivaroxaban	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Rivaroxaban.
Sulodexide	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Sulodexide.
Idraparinux	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Idraparinux.
Cangrelor	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Cangrelor.
Astaxanthin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Astaxanthin.
Apixaban	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Apixaban.
Otamixaban	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Otamixaban.
Amediplase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Amediplase.
Dabigatran etexilate	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dabigatran etexilate.
Danaparoid	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Danaparoid.
Dalteparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dalteparin.
Tinzaparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Tinzaparin.
(R)-warfarin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with (R)-warfarin.
Ethyl biscoumacetate	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Ethyl biscoumacetate.
Nadroparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Nadroparin.
Triflusal	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Triflusal.
Ticagrelor	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Ticagrelor.
Ditazole	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Ditazole.
Vorapaxar	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Vorapaxar.
Edoxaban	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Edoxaban.
Sodium citrate	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Sodium citrate.
Dextran	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dextran.
Bemiparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Bemiparin.
Parnaparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Parnaparin.
Desirudin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Desirudin.
Antithrombin Alfa	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Antithrombin Alfa.
Protein C	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Protein C.
Antithrombin III human	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Antithrombin III human.
Letaxaban	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Letaxaban.
Darexaban	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Darexaban.
Betrixaban	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Betrixaban.
Nafamostat	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Nafamostat.
Gabexate	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Gabexate.
Fluindione	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Fluindione.
Protein S human	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Protein S human.
Brinase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Brinase.
Clorindione	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Clorindione.
Diphenadione	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Diphenadione.
Tioclomarol	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Tioclomarol.
Melagatran	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Melagatran.
Saruplase	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Saruplase.
(S)-Warfarin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with (S)-Warfarin.
Tocopherylquinone	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Tocopherylquinone.
Dabigatran	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dabigatran.
Semuloparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Semuloparin.
Troxerutin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Troxerutin.
Edetic acid	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Edetic acid.
Reviparin	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Reviparin.
Dermatan sulfate	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Dermatan sulfate.
SR-123781A	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with SR-123781A.
Limaprost	The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Limaprost.

Target Protein

Coagulation factor VIII F8

Collagen alpha-1(I) chain COL1A1

Asialoglycoprotein receptor 1 ASGR1

Prolow-density lipoprotein receptor-related protein 1 LRP1

Referensi & Sumber

Artikel (PubMed)

PMID: 19768705
Clifton JG, Huang F, Kovac S, Yang X, Hixson DC, Josic D: Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates. Electrophoresis. 2009 Oct;30(20):3636-46. doi: 10.1002/elps.200900270.
PMID: 21220152
Klukowska A, Windyga J, Batorova A: Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate((R)), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Thromb Res. 2011 Mar;127(3):247-53. doi: 10.1016/j.thromres.2010.11.030. Epub 2011 Jan 8.
PMID: 25712991
Lenting PJ, Christophe OD, Denis CV: von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015 Mar 26;125(13):2019-28. doi: 10.1182/blood-2014-06-528406. Epub 2015 Feb 23.
PMID: 26239086
Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, Obermann-Slupetzky O, Chapman M, Fritsch S, Pavlova BG, Presch I, Ewenstein B: Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015 Oct 22;126(17):2038-46. doi: 10.1182/blood-2015-02-629873. Epub 2015 Aug 3.
PMID: 18263586
Chung MC, Popova TG, Jorgensen SC, Dong L, Chandhoke V, Bailey CL, Popov SG: Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy. J Biol Chem. 2008 Apr 11;283(15):9531-42. doi: 10.1074/jbc.M705871200. Epub 2008 Feb 8.

Link

Contoh Produk & Brand

Produk: 20 • International brands: 0

Produk

Alphanate

Powder, for solution • - • Intravenous • Canada • Approved
Alphanate

Powder, for solution • - • Intravenous • Canada • Approved
Alphanate

Powder, for solution • - • Intravenous • Canada • Approved
Alphanate

Powder, for solution • - • Intravenous • Canada • Approved
Alphanate

Powder, for solution • - • Intravenous • Canada • Approved
Humate-P

Powder, for solution • - • Intravenous • Canada • Approved
Humate-P

Powder, for solution • - • Intravenous • Canada • Approved
Humate-P

Powder, for solution • - • Intravenous • Canada • Approved

Menampilkan 8 dari 20 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.